Genetics

Independent Links for Genetics, Lifestyle With Incident Stroke

Independent Links for Genetics, Lifestyle With Incident Stroke

Genetic and lifestyle factors are independently associated with incident stroke among men and women aged 40 to 73 years.

Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer

Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer

Olaparib maintenance therapy after platinum chemotherapy substantially prolonged PFS compared with placebo in newly diagnosed advanced ovarian cancer.

Talzenna Approved for Germline <i>BRCA</i>-Mutated, <i>HER2</i>-Negative Breast Cancer

Talzenna Approved for Germline BRCA-Mutated, HER2-Negative Breast Cancer

By

Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or metastatic breast cancer (N=431) to receive talazoparib 1mg or physician's choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine).

FDA Approves New DNA-Based Test to Verify Blood Compatibility

FDA Approves New DNA-Based Test to Verify Blood Compatibility

Assay can be used to determine blood donor and patient non-ABO red blood cell types.

Genomic Screening Can ID Undetected <i>BRCA1/2</i> Cancer Risk

Genomic Screening Can ID Undetected BRCA1/2 Cancer Risk

82 percent of variant carriers identified in exome sequencing had not undergone prior testing.

Caring for Carriers: Do Direct-to-Consumer Genetic Test Results Have a Place in Primary Care?

Caring for Carriers: Do Direct-to-Consumer Genetic Test Results Have a Place in Primary Care?

By

A case and commentary published in the AMA Journal of Ethics discusses the ethics of primary care physician response to direct-to-consumer genetic testing results of concerned patients.

Talazoparib Shows Antitumor Activity in Advanced Breast Cancer, Germline <i>BRCA</i> Mutation

Talazoparib Shows Antitumor Activity in Advanced Breast Cancer, Germline BRCA Mutation

By

Talazoparib, a poly(adenosine diphosphate-ribose) inhibitor, may significantly enhance progression-free survival in patients with advanced breast cancer and a germline BRCA1/2 mutation.

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.

Tucatinib May Be A Safe, Novel Treatment for <i>ERBB2/HER2</i>-Positive Breast Cancer

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Age, Sex, <i>APOE</i> Genotype Identify Alzheimer's, Dementia Risk

Age, Sex, APOE Genotype Identify Alzheimer's, Dementia Risk

Three factors help identify absolute 10-year risk of Alzheimer's disease, all dementia for different groups.

Beyond <I>BRCA</i>: New Predisposition Genes Linked to Breast, Ovarian Cancers

Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers

By

Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.

Immune Cells' Gene Expression May Predict Flu Susceptibility

Immune Cells' Gene Expression May Predict Flu Susceptibility

Expression of KLRD1 by natural killer cells before infection associated with influenza severity.

Putting Genetics to the Test: Insurers vs Preexisting Conditions in the Age of Trump

Putting Genetics to the Test: Insurers vs Preexisting Conditions in the Age of Trump

Before the Affordable Care Act, insurance companies could deny coverage to patients based on genetic testing results.

Copy Number Abnormalities May Inform Survival, Drug Resistance

Copy Number Abnormalities May Inform Survival, Drug Resistance

For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.

Patient Interest Fairly High for Melanoma Genetic Risk Testing

Patient Interest Fairly High for Melanoma Genetic Risk Testing

Reduced interest seen in minority and less educated populations.

Ethics of Genealogy Data Use for Solving Crimes Discussed

Ethics of Genealogy Data Use for Solving Crimes Discussed

Ethical discussion relates to issues of informed consent, privacy, and justice

Genetic Risk Score Better Than APOE Alone for Assessing Risk for Alzheimer's Dementia

Genetic Risk Score Better Than APOE Alone for Assessing Risk for Alzheimer's Dementia

The genetic risk score primarily modified the risk for and onset of dementia and AD among homozygous carriers for APOE ε4.

A History of Race and the Emerging Role of Genetics in Primary Care

A History of Race and the Emerging Role of Genetics in Primary Care

In 2003, the Human Genome Project became the culmination of the history of genetics research, allowing us to understand the role of genetics in human health and disease. As part of The Clinical Advisor's 20th Anniversary, this article explores the influence of race and genetics in clinical practice.

Complete fetal genome sequences can be obtained from amniotic fluid

Complete fetal genome sequences can be obtained from amniotic fluid

Complete genome sequences were elucidated for 31 fetuses from amniotic fluid. Two methods of DNA extraction proved to be relatively equal in quality of complete genome sequence.

Ovarian cancer may be paternally inherited

Ovarian cancer may be paternally inherited

By

The disease allele may be passed from affected grandmother to granddaughter through the father's inherited genes.

Genetic testing: an overview for clinicians

Genetic testing: an overview for clinicians

Understanding genetic testing allows providers to make the most of this resource in patient care.

FDA approves first direct-to-consumer genetic health risk test

FDA approves first direct-to-consumer genetic health risk test

By

The test will provide information on an individual's genetic predisposition to 10 diseases or conditions.

ACOG issues recommendations for prenatal genetic screening, diagnostic testing

ACOG issues recommendations for prenatal genetic screening, diagnostic testing

By

Published practice bulletins offer guidance to clinicians on patient education during pregnancy.

Primary care clinician risk assessment for hereditary breast cancer

Primary care clinician risk assessment for hereditary breast cancer

Primary care clinicians should be proficient at assessing the potential for hereditary breast cancer risk in their patients.

Few women receive genetic counseling prior to BRCA test

Few women receive genetic counseling prior to BRCA test

Women who receive genetic counseling prior to undergoing BRCA testing display more knowledge of both the testing process and of the potential results.

Multigene tests can change breast, ovarian cancer management

Multigene tests can change breast, ovarian cancer management

For hereditary breast, ovarian cancer, multigene testing can influence clinical treatment options.

VNN1 gene may be potential biomarker for childhood asthma

VNN1 gene may be potential biomarker for childhood asthma

The activity of a gene called vanin-1 (VNN1) affected whether they were good or poor responders to corticosteroid treatment.

Researchers make headway on understanding body's response to allergies

Researchers make headway on understanding body's response to allergies

In the absence of Mbd2, dendritic cells display reduced phenotypic activation and a markedly impaired capacity to initiate immunity against helminthes or allergens.

Are shorter people at higher risk for developing coronary artery disease?

Are shorter people at higher risk for developing coronary artery disease?

There is a relative 13.5% increase in coronary artery disease risk for every 2.5 inches shaved off a person's height.

First neonatal SCID screening test approved by FDA

First neonatal SCID screening test approved by FDA

The Food and Drug Administration (FDA) has granted marketing of the EnLite Neonatal TREC Kit, the first FDA-cleared test to screen for severe combined immunodeficiency (SCID) in newborns.

Sign Up for Free e-newsletters